Marco Prinz;Wolfgang Bruck;Alexander Mildner;Matthias Mack
发明人:
Marco Prinz,Wolfgang Bruck,Alexander Mildner,Matthias Mack
申请号：
US12295718
公开号：
US09068002B2
申请日:
2007.04.02
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.
